Screening for factor V Leiden mutation before prescribing combination oral contraceptives

Mitchell D Creinin, Rachel Lisman, Ronald C. Strickler

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Objective: To evaluate the cost-effectiveness of screening for factor V Leiden mutation in women in the United States who use combination oral contraceptives. Design: Cost-effectiveness analysis. Setting: A national research reference laboratory, a university medical center, and an academic health center managed care organization. Patient(s): Women of reproductive age in the United States. Intervention(s): Baseline risk estimates of venous thromboembolic disease in the general population and in carriers of factor V Leiden mutation were calculated using available data. Main Outcome Measure(s): The number of women who would require factor V Leiden testing and the cost of identifying this cohort to prevent one death caused by venous thromboembolic disease before prescribing combination oral contraceptives. Result(s): To prevent one venous thromboembolic death attributable to the use of oral contraceptives in women with factor V Leiden mutation, >92,000 carriers would need to be identified and stopped from using these pills. The estimated charge to prevent this one death would exceed $300 million. If the price of testing were discounted to 34.5% of current charges, the cost still would be between $105 million and $130 million. Conclusion(s): Screening for factor V Leiden mutation before prescribing combination oral contraceptives is not a cost-effective use of U.S. health care dollars. The best and most cost-effective screening tool we have is taking a thorough personal and family history related to venous thromboembolic events.

Original languageEnglish (US)
Pages (from-to)646-651
Number of pages6
JournalFertility and Sterility
Volume72
Issue number4
DOIs
StatePublished - Oct 1999
Externally publishedYes

Fingerprint

Oral Contraceptives
Mutation
Costs and Cost Analysis
Cost-Benefit Analysis
Managed Care Programs
Outcome Assessment (Health Care)
factor V Leiden
Organizations
Delivery of Health Care
Health
Research
Population

Keywords

  • Factor V Leiden
  • Hypercoagulability
  • Oral contraceptives
  • Venous thromboembolism

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Screening for factor V Leiden mutation before prescribing combination oral contraceptives. / Creinin, Mitchell D; Lisman, Rachel; Strickler, Ronald C.

In: Fertility and Sterility, Vol. 72, No. 4, 10.1999, p. 646-651.

Research output: Contribution to journalArticle

@article{9c263f49b7034d73b0b98a2bd9b931cd,
title = "Screening for factor V Leiden mutation before prescribing combination oral contraceptives",
abstract = "Objective: To evaluate the cost-effectiveness of screening for factor V Leiden mutation in women in the United States who use combination oral contraceptives. Design: Cost-effectiveness analysis. Setting: A national research reference laboratory, a university medical center, and an academic health center managed care organization. Patient(s): Women of reproductive age in the United States. Intervention(s): Baseline risk estimates of venous thromboembolic disease in the general population and in carriers of factor V Leiden mutation were calculated using available data. Main Outcome Measure(s): The number of women who would require factor V Leiden testing and the cost of identifying this cohort to prevent one death caused by venous thromboembolic disease before prescribing combination oral contraceptives. Result(s): To prevent one venous thromboembolic death attributable to the use of oral contraceptives in women with factor V Leiden mutation, >92,000 carriers would need to be identified and stopped from using these pills. The estimated charge to prevent this one death would exceed $300 million. If the price of testing were discounted to 34.5{\%} of current charges, the cost still would be between $105 million and $130 million. Conclusion(s): Screening for factor V Leiden mutation before prescribing combination oral contraceptives is not a cost-effective use of U.S. health care dollars. The best and most cost-effective screening tool we have is taking a thorough personal and family history related to venous thromboembolic events.",
keywords = "Factor V Leiden, Hypercoagulability, Oral contraceptives, Venous thromboembolism",
author = "Creinin, {Mitchell D} and Rachel Lisman and Strickler, {Ronald C.}",
year = "1999",
month = "10",
doi = "10.1016/S0015-0282(99)00318-0",
language = "English (US)",
volume = "72",
pages = "646--651",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Screening for factor V Leiden mutation before prescribing combination oral contraceptives

AU - Creinin, Mitchell D

AU - Lisman, Rachel

AU - Strickler, Ronald C.

PY - 1999/10

Y1 - 1999/10

N2 - Objective: To evaluate the cost-effectiveness of screening for factor V Leiden mutation in women in the United States who use combination oral contraceptives. Design: Cost-effectiveness analysis. Setting: A national research reference laboratory, a university medical center, and an academic health center managed care organization. Patient(s): Women of reproductive age in the United States. Intervention(s): Baseline risk estimates of venous thromboembolic disease in the general population and in carriers of factor V Leiden mutation were calculated using available data. Main Outcome Measure(s): The number of women who would require factor V Leiden testing and the cost of identifying this cohort to prevent one death caused by venous thromboembolic disease before prescribing combination oral contraceptives. Result(s): To prevent one venous thromboembolic death attributable to the use of oral contraceptives in women with factor V Leiden mutation, >92,000 carriers would need to be identified and stopped from using these pills. The estimated charge to prevent this one death would exceed $300 million. If the price of testing were discounted to 34.5% of current charges, the cost still would be between $105 million and $130 million. Conclusion(s): Screening for factor V Leiden mutation before prescribing combination oral contraceptives is not a cost-effective use of U.S. health care dollars. The best and most cost-effective screening tool we have is taking a thorough personal and family history related to venous thromboembolic events.

AB - Objective: To evaluate the cost-effectiveness of screening for factor V Leiden mutation in women in the United States who use combination oral contraceptives. Design: Cost-effectiveness analysis. Setting: A national research reference laboratory, a university medical center, and an academic health center managed care organization. Patient(s): Women of reproductive age in the United States. Intervention(s): Baseline risk estimates of venous thromboembolic disease in the general population and in carriers of factor V Leiden mutation were calculated using available data. Main Outcome Measure(s): The number of women who would require factor V Leiden testing and the cost of identifying this cohort to prevent one death caused by venous thromboembolic disease before prescribing combination oral contraceptives. Result(s): To prevent one venous thromboembolic death attributable to the use of oral contraceptives in women with factor V Leiden mutation, >92,000 carriers would need to be identified and stopped from using these pills. The estimated charge to prevent this one death would exceed $300 million. If the price of testing were discounted to 34.5% of current charges, the cost still would be between $105 million and $130 million. Conclusion(s): Screening for factor V Leiden mutation before prescribing combination oral contraceptives is not a cost-effective use of U.S. health care dollars. The best and most cost-effective screening tool we have is taking a thorough personal and family history related to venous thromboembolic events.

KW - Factor V Leiden

KW - Hypercoagulability

KW - Oral contraceptives

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=0033214004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033214004&partnerID=8YFLogxK

U2 - 10.1016/S0015-0282(99)00318-0

DO - 10.1016/S0015-0282(99)00318-0

M3 - Article

C2 - 10521103

AN - SCOPUS:0033214004

VL - 72

SP - 646

EP - 651

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 4

ER -